MedTrace Logo

Randomized Double Blind Placebo Controlled Clinical Trial to Evaluate Obese and Overweight Subjects

NCT04375696 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2022-11-22

No results posted yet for this study

Summary

The purpose of the study is to evaluate the effect on weight loss in a group of subjects suffering from overweight and mild obesity (BMI between 25 and 32 Kg/m2) and with weight \> 75 Kg/m2 being administered with a 3 g/day polyglucosamine dosage.

Conditions

Interventions

DRUG

Polyglucosamine L112

Polyglucosamine; Ascorbic Acid; Tartaric Acid

OTHER

Placebo

Dicalcium Phosphate; Microcrystalline Cellulose; Iron Oxide (yellow, brown, and black); Magnesium Stearate; Silicon Dioxide

Sponsors & Collaborators

  • Certmedica International GmbH

    lead INDUSTRY

Principal Investigators

  • Mariangela Rondanelli, Prof. · University of Pavia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-04-24
Primary Completion
2021-12-20
Completion
2021-12-20

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04375696 on ClinicalTrials.gov